Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04214886 · ClinicalTrials.gov registry record · Phase 1

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

A Phase 1 study of B-Cell Acute Lymphoblastic Leukemia, Adult and B-cell Lymphoma Refractory, sponsored by Loyola University.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT04214886 is a Phase 1 study of B-Cell Acute Lymphoblastic Leukemia, Adult and B-cell Lymphoma Refractory that is active but no longer recruiting, run by Loyola University. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04214886, a Phase 1 study of B-Cell Acute Lymphoblastic Leukemia, Adult and B-cell Lymphoma Refractory, is active but no longer recruiting, sponsored by Loyola University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting.

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • BIOLOGICAL CD19-CD34 CAR transduced T cells

Study Locations (1)

Illinois

  • Loyola University - Maywood

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2019-12-31
Est. Completion 2034-12-31
Phase Phase 1

Sponsor

Loyola University

92 total trials

What the Registry Record Tells You About NCT04214886

The ClinicalTrials.gov registry entry for NCT04214886 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with B-Cell Acute Lymphoblastic Leukemia, Adult appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT04214886 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT04214886 about?

NCT04214886 is a clinical study titled "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies". In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are...

What is the current status of trial NCT04214886?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-12-31. Estimated completion is 2034-12-31.

What conditions does trial NCT04214886 study?

This clinical trial studies the following conditions: B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent.

What interventions are being tested in trial NCT04214886?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), CD19-CD34 CAR transduced T cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT04214886?

This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04214886 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for B-Cell Acute Lymphoblastic Leukemia, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.